188 related articles for article (PubMed ID: 28196297)
41. [Key role of nicotinamide phosphoribosyltransferase (NAMPT) and NAD metabolism in the transition of melanoma cells to an invasive and drug-resistant phenotype].
Bertolotto C; Ohanna M; Ballotti R
Med Sci (Paris); 2018 Dec; 34(12):1025-1028. PubMed ID: 30623759
[No Abstract] [Full Text] [Related]
42. MIA--a new target protein for malignant melanoma therapy.
Schmidt J; Riechers A; Bosserhoff AK
Histol Histopathol; 2013 Apr; 28(4):421-6. PubMed ID: 23192727
[TBL] [Abstract][Full Text] [Related]
43. PAX3 knockdown in metastatic melanoma cell lines does not reduce MITF expression.
He S; Li CG; Slobbe L; Glover A; Marshall E; Baguley BC; Eccles MR
Melanoma Res; 2011 Feb; 21(1):24-34. PubMed ID: 21164369
[TBL] [Abstract][Full Text] [Related]
44. BRN2, a POUerful driver of melanoma phenotype switching and metastasis.
Fane ME; Chhabra Y; Smith AG; Sturm RA
Pigment Cell Melanoma Res; 2019 Jan; 32(1):9-24. PubMed ID: 29781575
[TBL] [Abstract][Full Text] [Related]
45. Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state.
Verfaillie A; Imrichova H; Atak ZK; Dewaele M; Rambow F; Hulselmans G; Christiaens V; Svetlichnyy D; Luciani F; Van den Mooter L; Claerhout S; Fiers M; Journe F; Ghanem GE; Herrmann C; Halder G; Marine JC; Aerts S
Nat Commun; 2015 Apr; 6():6683. PubMed ID: 25865119
[TBL] [Abstract][Full Text] [Related]
46. Mitf regulation of Dia1 controls melanoma proliferation and invasiveness.
Carreira S; Goodall J; Denat L; Rodriguez M; Nuciforo P; Hoek KS; Testori A; Larue L; Goding CR
Genes Dev; 2006 Dec; 20(24):3426-39. PubMed ID: 17182868
[TBL] [Abstract][Full Text] [Related]
47. A novel stilbene-like compound that inhibits melanoma growth by regulating melanocyte differentiation and proliferation.
Stueven NA; Schlaeger NM; Monte AP; Hwang SL; Huang CC
Toxicol Appl Pharmacol; 2017 Dec; 337():30-38. PubMed ID: 29042215
[TBL] [Abstract][Full Text] [Related]
48. Metastatic potential of human melanoma cells in nude mice--characterisation of phenotype, cytokine secretion and tumour-associated antigens.
Schadendorf D; Fichtner I; Makki A; Alijagic S; Küpper M; Mrowietz U; Henz BM
Br J Cancer; 1996 Jul; 74(2):194-9. PubMed ID: 8688321
[TBL] [Abstract][Full Text] [Related]
49. Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny.
Cheli Y; Giuliano S; Botton T; Rocchi S; Hofman V; Hofman P; Bahadoran P; Bertolotto C; Ballotti R
Oncogene; 2011 May; 30(20):2307-18. PubMed ID: 21278797
[TBL] [Abstract][Full Text] [Related]
50. [Malignant melanoma and the role of the paradoxal protein Microphthalmia transcription factor].
Denat L; Larue L
Bull Cancer; 2007 Jan; 94(1):81-92. PubMed ID: 17237008
[TBL] [Abstract][Full Text] [Related]
51. Transglutaminase Type 2-MITF axis regulates phenotype switching in skin cutaneous melanoma.
Muccioli S; Brillo V; Varanita T; Rossin F; Zaltron E; Velle A; Alessio G; Angi B; Severin F; Tosi A; D'Eletto M; Occhigrossi L; Falasca L; Checchetto V; Ciaccio R; Fascì A; Chieregato L; Rebelo AP; Giacomello M; Rosato A; Szabò I; Romualdi C; Piacentini M; Leanza L
Cell Death Dis; 2023 Oct; 14(10):704. PubMed ID: 37898636
[TBL] [Abstract][Full Text] [Related]
52. A novel role for microphthalmia-associated transcription factor-regulated pigment epithelium-derived factor during melanoma progression.
Dadras SS; Lin RJ; Razavi G; Kawakami A; Du J; Feige E; Milner DA; Loda MF; Granter SR; Detmar M; Widlund HR; Horstmann MA; Fisher DE
Am J Pathol; 2015 Jan; 185(1):252-65. PubMed ID: 25447045
[TBL] [Abstract][Full Text] [Related]
53. Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching.
Eichhoff OM; Weeraratna A; Zipser MC; Denat L; Widmer DS; Xu M; Kriegl L; Kirchner T; Larue L; Dummer R; Hoek KS
Pigment Cell Melanoma Res; 2011 Aug; 24(4):631-42. PubMed ID: 21599871
[TBL] [Abstract][Full Text] [Related]
54. Nucleotide stress responses in neural crest cell fate and melanoma.
Sporrij A; Zon LI
Cell Cycle; 2021 Aug; 20(15):1455-1467. PubMed ID: 34281491
[TBL] [Abstract][Full Text] [Related]
55. Nucleosome assembly protein 1-like 4, a new therapeutic target for proliferation and invasion of melanoma cells.
Mizuhashi S; Fukushima S; Ishibashi T; Kuriyama H; Kimura T; Kanemaru H; Kajihara I; Makino K; Miyashita A; Aoi J; Kita K; Ihn H
J Dermatol Sci; 2021 Apr; 102(1):16-24. PubMed ID: 33583643
[TBL] [Abstract][Full Text] [Related]
56. WNT5A induces release of exosomes containing pro-angiogenic and immunosuppressive factors from malignant melanoma cells.
Ekström EJ; Bergenfelz C; von Bülow V; Serifler F; Carlemalm E; Jönsson G; Andersson T; Leandersson K
Mol Cancer; 2014 Apr; 13():88. PubMed ID: 24766647
[TBL] [Abstract][Full Text] [Related]
57. Gene expression analyses of primary melanomas reveal CTHRC1 as an important player in melanoma progression.
Eriksson J; Le Joncour V; Nummela P; Jahkola T; Virolainen S; Laakkonen P; Saksela O; Hölttä E
Oncotarget; 2016 Mar; 7(12):15065-92. PubMed ID: 26918341
[TBL] [Abstract][Full Text] [Related]
58. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
Wang AX; Qi XY
IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
[TBL] [Abstract][Full Text] [Related]
59. MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines.
Vultur A; Villanueva J; Krepler C; Rajan G; Chen Q; Xiao M; Li L; Gimotty PA; Wilson M; Hayden J; Keeney F; Nathanson KL; Herlyn M
Oncogene; 2014 Apr; 33(14):1850-61. PubMed ID: 23624919
[TBL] [Abstract][Full Text] [Related]
60. Association of MITF and other melanosome-related proteins with chemoresistance in melanoma tumors and cell lines.
Hertzman Johansson C; Azimi A; Frostvik Stolt M; Shojaee S; Wiberg H; Grafström E; Hansson J; Egyházi Brage S
Melanoma Res; 2013 Oct; 23(5):360-5. PubMed ID: 23921446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
